Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:02 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 4,225 matching trials from the local directory fallback.

Filters: Intervention: Placebo Clear all

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration; Drug · Procedure · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 41
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more

Conditions: Expectations, Negative Affectivity, Non-invasive Brain Stimulation, Placebo Effect
Interventions: Session A: Positive Placebo + Active tTIS, Session B: Positive Placebo + Sham tTIS, Session C: Negative Placebo + Active tTIS, Session D: Negative Placebo + Sham tTIS, Session E: On-Placebo + Sham tTIS, Session F: Off-Placebo + Sham tTIS; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years to 55 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Hanover, New Hampshire

Conditions: Cognitive Decline, Cognitive Dysfunction
Interventions: Placebo Supplement, Polyphenol Supplement; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Anxiety, Depression, Pain, Sleep
Interventions: Placebo, bsCBD Cannabidiol, fsCBD Cannabidiol; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 60 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Colitis, Immune-related Colitis
Interventions: Placebo, RMT; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Brainerd, Minnesota • Deer River, Minnesota • Detroit Lakes, Minnesota + 6 more

Conditions: ACL Injury, Meniscus Tear, Post-traumatic Osteoarthritis
Interventions: Montelukast, Placebo; Drug
Lead sponsor: Austin V Stone; Other
Eligibility: 25 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Obesity
Interventions: MBX 4291, Placebo; Drug
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Doral, Florida • Lexington, Kentucky • Kansas City, Missouri + 1 more

Conditions: Multiple Sclerosis, Multiple Sclerosis Fatigue
Interventions: Placebo, Solriamfetol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bone Loss
Interventions: Bisphosphonate, Placebo, Resistance Training/Bone-Loading Exercise; Drug · Other · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Winston-Salem, North Carolina

Conditions: Pain, Postoperative
Interventions: Morphine Sulfate, Placebo; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Knee Arthritis
Interventions: Cannabidiol (CBD), Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Amputation, Skin Wound, Stem Cell
Interventions: Autologous Skin Fibroblasts, Placebo; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Narcolepsy Type 1 (NT1)
Interventions: Bupropion, Midazolam, Placebo, VX-433; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Thoracic Aortic Aneurysm
Interventions: Placebo, Spironolactone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Clinical High Risk for Psychosis (CHR)
Interventions: MT1988 High Dose, MT1988 Low Dose, Placebo; Drug
Lead sponsor: Monument Therapeutics Limited; Industry
Eligibility: 17 Years to 30 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 10 more

Conditions: Cocaine Use Disorder
Interventions: Cocaine (IV), Pentoxifylline, Placebo; Drug
Lead sponsor: William Stoops; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Methamphetamine Use Disorder
Interventions: Methamphetamine, Placebo; Drug
Lead sponsor: William Stoops; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chronic Kidney Disease, Pediatric Urology
Interventions: NSAIDs, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Months to 25 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, Ranolazine; Drug
Lead sponsor: Swathy Chandrashekhar, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Jacksonville, Florida • Fairway, Kansas + 3 more

Conditions: Alcohol Use Disorder
Interventions: Alcohol, Placebo, Suvorexant; Drug
Lead sponsor: William Stoops; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Quiescent Crohn's Disease (CD)
Interventions: Amitriptyline, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Insomnia Disorder
Interventions: Placebo, Tasimelteon Oral Suspension; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Dothan, Alabama • Phoenix, Arizona • Irvine, California + 17 more

Conditions: Delayed Sleep Phase Syndrome
Interventions: Lemborexant, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Corneal Ulcer, Fungal Keratitis
Interventions: Cyclosporine A, Placebo Comparator: Placebo; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Neural Mechanisms of Interpersonal Expectations on Negative Affect

Polyphenols and Cognitive Decline

Cannabidiol and Older Adult Cannabis Users

A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Bone, Exercise, Alendronate, and Caloric Restriction

Intrathecal Morphine for Analgesia in Video-assisted and Robotic-assisted Thoracic Surgery

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

Autologous Volar Fibroblast Injection Into the Stump Site of Amputees

A Phase 1, First-in-human Study of VX-433

HEART: Pilot Randomized Controlled Trial

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Cocaine and Pentoxifylline (BED IN 47)

Methamphetamine and Troriluzole

Safety of Short-course of NSAIDs in Pediatric Patients With CKD

A Study of Ranolazine in ALS

Suvorexant and Alcohol

Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Lemborexant in Delayed Sleep Phase Syndrome

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A